title: Growth hormone effect on body composition in Turner syndrome.
abstract: This study analyzes the body composition of young adult women with Turner syndrome (TS) either treated or not treated with recombinant human growth hormone (rhGH) and compares them with a group of healthy women. Fifty-two non-treated TS patients (23.0 ± 5.8 years), 30 treated with rhGH (21.5 ± 1.5 years), and 133 healthy young adult women (22.9 ± 3.2 years) were evaluated regarding height (H) and weight, body mass index (BMI), brachial perimeter and tricipital cutaneous fold (fat and lean areas at the arm), sitting height (SRH = sitting height/H × 100), leg length (leg/H), waist and hip circumferences (waist/hip), and bioimpedance (percentages of water, lean mass, and fat mass). Age at start of rhGH therapy varied from 7.8 to 15.1 years (10.0 ± 1.3 years), duration of treatment from 2.8 to 8.2 years (3.7 ± 1.5 years), and the mean dose was 0.42 mg/kg/w (from 0.32 to 0.50 mg/kg/w). Body composition (except height) did not differ between TS groups, but there were differences when compared to the control group: weight and sitting height were lower in TS patients; and BMI, SHR, and leg/H were higher. There was an association between all groups with regards to BMI, waist, SHR, and leg/H, but not in percentage of fat mass. SHR was positively correlated with BMI, waist, hip, and percentage of fat mass. This sample of TS patients (with and without rhGH therapy) did not differ in BMI or body composition. However, there were differences between patients with TS patients and normal healthy women. Regardless of rhGH therapy, TS patients should be monitored, particularly for sitting height, SHR, leg length, leg/H, and waist/hip.
authors: Pediatric Endocrinology Unit, Department of Pediatrics and Center for Investigation in Pediatrics, Faculty of Medical Sciences (FCM), State University of Campinas (UNICAMP), Campinas, SP, 13083-970, Brazil.
authors: Alexandre Duarte
authors: AD
authors: Baldin
authors: Tatiana
authors: T
authors: Fabbri
authors: Adriana Aparecida
authors: AA
authors: Siviero-Miachon
authors: Angela Maria
authors: AM
authors: Spinola-Castro
authors: Sofia Helena Valente
authors: SH
authors: de Lemos-Marini
authors: Maria Tereza Matias
authors: MT
authors: Baptista
authors: Lilia Freire Rodrigues
authors: LF
authors: D'Souza-Li
authors: Andrea Trevas
authors: AT
authors: Maciel-Guerra
authors: Gil
authors: G
authors: Guerra-Junior
mesh_terms: D000293:Adolescent; D000328:Adult; D001823:Body Composition / Q000187:drug effects* / Q000502:physiology; D050218:Body Fat Distribution; D015992:Body Mass Index; D016022:Case-Control Studies; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D006130:Growth Disorders / Q000150:complications / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008137:Longitudinal Studies; D016555:Matched-Pair Analysis; D011994:Recombinant Proteins; D012016:Reference Values; D014424:Turner Syndrome / Q000150:complications* / Q000188:drug therapy; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D019382:Human Growth Hormone